14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ACHV vs OLMA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ACHV Overall Winner
6-Pillar Tally: ACHV 3 – 2 OLMA (1 Tie)
Matrix Metrics: ACHV 6 – 1 OLMA
As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) is the stronger overall head-to-head candidate over Olema Pharmaceuticals, Inc. (OLMA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas OLMA carries 47.0/100 (HOLD) at $7.25 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile OLMA is in a Breakdown options structure phase (RSI 45.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs OLMA. Trailing 12-month operating profitability (ACHV 0.0% vs OLMA 0.0%) and valuation multiples (ACHV 35.3x vs OLMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
OLMA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $658.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ACHV vs OLMA Key Questions & Quantitative Answers
As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) is the stronger overall head-to-head candidate over Olema Pharmaceuticals, Inc. (OLMA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas OLMA carries 47.0/100 (HOLD) at $7.25 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile OLMA is in a Breakdown options structure phase (RSI 45.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACHV leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OLMA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus N/A for OLMA. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OLMA.
ACHV screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas OLMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus OLMA (-69.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, OLMA carries 271.2% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 5.70x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.84β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.